Crinetics Pharmaceuticals, Inc.(CRNX)

$84.70—

Chart

Crinetics Pharmaceuticals, Inc.(CRNX)

NASDAQ

$84.70—

Chart Studio

CRNX(CRNX)

CRNX

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-1.20

Nov 5, 2026 · Reports after close

Revenue Estimate

$21M

FY2029E EPS$0.98

FY2030E EPS$4.54

Analyst Sentiment

Wall St. Consensus

Buy

19 analysts·Moderate coverage

Score

13 Buy (68%)6 Hold (32%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

1368%

Hold

632%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$84.00

-0.8%

Consensus

$85.00

+0.4%

Bull

$85.00

+0.4%

12-Month Target Range19 analysts

$84.00$85.00$85.00

Current $84.70Consensus

Current Price

$84.70

Upside to Consensus

$0.30

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+151.01%

EPS—

FY2028

Rev+142.79%

EPS—

FY2029

Rev+119.23%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$69M	$172M	$418M	$916M	$1.56B
Low	$64M	$132M	$326M	$703M	$1.20B
High	$75M	$213M	$592M	$1.17B	$1.99B
EBITDA Avg	$-69M	$-172M	$-418M	$-916M	$-1.56B
Low	$-75M	$-213M	$-592M	$-1.17B	$-1.99B
High	$-64M	$-132M	$-326M	$-703M	$-1.20B
EBIT Avg	$-69M	$-172M	$-418M	$-916M	$-1.56B
Low	$-75M	$-213M	$-592M	$-1.17B	$-1.99B
High	$-64M	$-132M	$-326M	$-703M	$-1.20B
Net Income Avg	$-424M	$-371M	$-275M	$92M	$427M
Low	$-477M	$-430M	$-308M	$64M	$297M
High	$-374M	$-311M	$-64M	$125M	$579M
EPS Avg	$-4.66	$-4.05	$-2.23	$0.98	$4.54
Low	$-5.07	$-4.58	$-3.27	$0.68	$3.16
High	$-3.97	$-3.30	$-0.68	$1.33	$6.16
Analysts (Rev / EPS)	2 / 11	10 / 10	8 / 6	6 / 3	6 / 2

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$19M	$23M	$27M	$37M	$46M	$56M
Low	$16M	$21M	$25M	$34M	$43M	$52M
High	$21M	$26M	$30M	$40M	$50M	$62M
EBITDA Avg	$-19M	$-23M	$-27M	$-37M	$-46M	$-56M
Low	$-21M	$-26M	$-30M	$-40M	$-50M	$-62M
High	$-16M	$-21M	$-25M	$-34M	$-43M	$-52M
EBIT Avg	$-19M	$-23M	$-27M	$-37M	$-46M	$-56M
Low	$-21M	$-26M	$-30M	$-40M	$-50M	$-62M
High	$-16M	$-21M	$-25M	$-34M	$-43M	$-52M
Net Income Avg	$-124M	$-123M	$-112M	$-105M	$-101M	$-94M
Low	$-137M	$-142M	$-125M	$-117M	$-113M	$-105M
High	$-97M	$-97M	$-100M	$-94M	$-91M	$-84M
EPS Avg	$-1.17	$-1.16	$-1.06	$-0.99	$-0.96	$-0.89
Low	$-1.30	$-1.35	$-1.19	$-1.11	$-1.07	$-1.00
High	$-0.92	$-0.92	$-0.95	$-0.89	$-0.86	$-0.80
Analysts (Rev / EPS)	3 / 9	5 / 9	4 / 6	4 / 3	4 / 3	4 / 6

Earnings Surprises

Recent Analyst Actions

Jul 28, 2026UBS

Crinetics downgraded to Neutral from Buy at UBS

Target:$85.00

+1.4%from $83.85

Jul 8, 2026Stifel Nicolaus

Crinetics downgraded to Hold from Buy at Stifel

Target:$85.00

+1.8%from $83.50

Jul 8, 2026Evercore ISI

Crinetics downgraded to In Line from Outperform at Evercore ISI

Target:$85.00

+1.8%from $83.53

Jul 7, 2026Jefferies

Crinetics downgraded to Hold from Buy at Jefferies

Target:$85.00

+102.2%from $42.03

Jul 7, 2026H.C. Wainwright

Crinetics downgraded to Neutral from Buy at H.C. Wainwright

Target:$85.00

+102.2%from $42.03

Jul 7, 2026Robert W. Baird

Crinetics price target raised to $85 from $62 at Baird

Target:$85.00

+102.2%from $42.03

Jul 2, 2026UBS

Crinetics initiated with a Buy at UBS

Target:$55.00

+42.2%from $38.68

Jun 22, 2026Stifel Nicolaus

Stifel Reiterates Buy Rating on Crinetics (CRNX)

Target:$83.00

+130.2%from $36.06

Jun 15, 2026H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Crinetics (CRNX)

Target:$81.00

+135.0%from $34.47

May 15, 2026Evercore ISI

Crinetics price target lowered to $88 from $89 at Evercore ISI

Target:$88.00

+133.4%from $37.71

May 11, 2026Oppenheimer

Crinetics price target lowered to $84 from $87 at Oppenheimer

Target:$84.00

+122.3%from $37.80

Jan 30, 2026Stifel Nicolaus

Crinetics price target raised to $84 from $75 at Stifel

Target:$84.00

+60.2%from $52.44

Jan 12, 2026Goldman Sachs

Crinetics upgraded to Buy from Neutral at Goldman Sachs

Target:$67.00

+25.8%from $53.25

Jan 8, 2026Morgan Stanley

Crinetics price target raised to $87 from $80 at Morgan Stanley

Target:$87.00

+64.7%from $52.82

Jan 8, 2026China Renaissance Securities (US) Inc.

Crinetics (CRNX) PT Lowered to $105 at Citizens: Palsonify Experience Positive

Target:$105.00

+96.9%from $53.34

Jan 5, 2026Evercore ISI

Crinetics price target raised to $90 from $80 at Evercore ISI

Target:$90.00

+75.6%from $51.26

Jan 5, 2026Stifel Nicolaus

Stifel Reiterates Buy Rating on Crinetics (CRNX)

Target:$75.00

+48.3%from $50.57

Sep 30, 2025Oppenheimer

Crinetics price target raised to $87 from $73 at Oppenheimer

Target:$87.00

+100.0%from $43.51

Sep 28, 2025Morgan Stanley

Crinetics price target raised to $77 from $65 at Morgan Stanley

Target:$77.00

+67.7%from $45.91

Sep 26, 2025JMP Securities

Crinetics price target raised to $143 from $86 at Citizens JMP

Target:$143.00

+211.5%from $45.91

Jul 10, 2025Goldman Sachs

Crinetics initiated with a Neutral at Goldman Sachs

Target:$36.00

+12.5%from $31.99

Mar 24, 2025Stifel Nicolaus

Crinetics initiated with a Buy at Stifel

Target:$60.00

+66.9%from $35.94

Feb 28, 2025JMP Securities

Crinetics price target lowered to $91 from $92 at Citizens JMP

Target:$91.00

+154.3%from $35.78

Aug 9, 2024H.C. Wainwright

Crinetics price target raised to $69 from $60 at H.C. Wainwright

Target:$69.00

+36.0%from $50.74

Jun 4, 2024Oppenheimer

Crinetics price target raised to $74 from $55 at Oppenheimer

Target:$74.00

+59.9%from $46.28

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance